Afraxis Hopes Experimental Fragile X Drug Could Apply To Other CNS Diseases
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech believes that inactivation of p21-activated kinase may address underlying cause of Fragile X syndrome.